Wells Fargo & Company Karyopharm Therapeutics Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 14 shares of KPTI stock, worth $13. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14
Previous 33,898
99.96%
Holding current value
$13
Previous $51,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding KPTI
# of Institutions
115Shares Held
64.5MCall Options Held
500KPut Options Held
99K-
Vanguard Group Inc Valley Forge, PA7.65MShares$7.12 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.1MShares$4.75 Million0.56% of portfolio
-
Eversept Partners, LP New York, NY4.99MShares$4.64 Million0.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.32MShares$4.02 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.17MShares$3.88 Million0.0% of portfolio
About Karyopharm Therapeutics Inc.
- Ticker KPTI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,806,600
- Market Cap $74.2M
- Description
- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...